Label Value
DOI 10.1186/s12931-019-0985-2
TITLE Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective
TYPE article
Service Status Date Last Checked
Scopus Yes 2019-05-22T02:41:30.442817
Web of Science Yes 2019-05-22T03:14:18.734317
Compendex No 2020-12-23T15:16:34.390097